The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Mitigating Cardiovascular Risk in Obesity
October 13th 2023Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.
Determining Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure, with Ankeet Bhatt, MD, MBA
October 10th 2023Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.
REBALANCE-HF: Greater Splanchnic Nerve Ablation Could Prove Beneficial in HFpEF
October 8th 2023The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.
Out-of-Pocket Costs Influence GDMT Uptake in Heart Failure, with Anand Shah, MD, MBA
October 7th 2023Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.
In Heart Failure Patients, Spironolactone Linked to Reduced Risk of Dementia, Alzheimers Disease
October 7th 2023A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.